PreveCeutical Medical Inc. PRVCF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -67.58% | -40.41% | 413.35% | 203.03% | 387.25% |
| Depreciation & Amortization | 3.45% | 36.36% | 44.44% | 36.84% | 61.11% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -67.03% | -38.75% | 394.25% | 203.20% | 364.88% |
| Operating Income | 67.03% | 38.75% | -394.25% | -203.20% | -364.88% |
| Income Before Tax | 56.88% | 25.84% | 592.82% | -153.05% | -242.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.88% | 25.84% | 592.82% | -153.05% | -242.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.43% | 25.84% | 637.02% | -153.05% | -231.76% |
| EBIT | 67.03% | 38.75% | -394.25% | -203.20% | -364.88% |
| EBITDA | 67.28% | 39.11% | -401.11% | -205.09% | -367.90% |
| EPS Basic | 60.00% | 30.00% | 633.33% | -120.00% | -200.00% |
| Normalized Basic EPS | 55.56% | 33.33% | -150.00% | -133.33% | -200.00% |
| EPS Diluted | 60.00% | 30.00% | 633.33% | -120.00% | -200.00% |
| Normalized Diluted EPS | 55.56% | 33.33% | -150.00% | -133.33% | -200.00% |
| Average Basic Shares Outstanding | 5.88% | 12.47% | 10.98% | 6.55% | 6.06% |
| Average Diluted Shares Outstanding | 5.88% | 12.47% | 10.98% | 6.55% | 6.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |